AUTHORS
Nikhila Sampath Kumar, MBBS, Cesar Gentille Sanchez, MD2
AFFILIATIONS
1 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
2 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
ABSTRACT
Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening hyperinflammatory syndrome that has been well described in peripheral T-cell lymphomas but remains poorly characterized in cutaneous T-cell lymphomas (CTCL). We evaluated the incidence, clinical characteristics, treatment patterns, and survival outcomes of HLH among patients with CTCL in a large real-world cohort.
Methods: We conducted a retrospective cohort study using the TriNetX federated electronic health record network. Adult patients with CTCL, including mycosis fungoides/Sézary syndrome (MF/SS), subcutaneous panniculitis-like T-cell lymphoma (SPTCL), primary cutaneous CD30-positive T-cell proliferations, and CTCL not otherwise specified (CTCL-NOS), were identified using validated diagnostic codes. First, a 10-year risk ratio of HLH (ICD-10 D76.1) among CTCL patients was calculated. The incidence of HLH occurring within 1 year of CTCL diagnosis was calculated separately for each subtype after excluding patients with a prior history of HLH. Patients with HLH diagnosed from 14 days before the initial CTCL diagnosis were included in the cohort to represent HLH as a herald sign of T-cell lymphomas. Baseline demographic characteristics, treatment patterns, and survival outcomes were evaluated using exploratory analyses. Patients with index events occurring more than 20 years before data extraction were excluded. Overall survival at the end of 1 year and 3 years was compared between CTCL patients with and without HLH using 1:1 propensity score matching based on demographic and clinical characteristics. Primary cutaneous gamma-delta T-cell lymphoma was considered in initial analysis but eventually excluded owing to small sample size (<10 patients) and no HLH cases at the end of 1 year from diagnosis.
Results: Between 8/4/2016 and 8/4/2026, a total of 26518 patient were recorded as having CTCL on this electronic health record, of which 74 developed HLH within a year of the CTCL diagnosis (RR: 0.279%). Outside of this 10-year analysis, a total of 129 patients with CTCL were identified, who developed HLH within one year of CTCL diagnosis. The HLH cohort comprised 57 (44.1%) patients with mycosis fungoides/sezary syndrome, 31 (24.03%) with SPTCL, 30 (23.2%) with CTCL-NOS and 11 (8.5%) with primary cutaneous CD30-positive T-cell proliferations.
Patients with HLH were substantially younger than those without HLH (mean age 46.3 ± 19.0 vs 59.1 ± 17.0 years). The HLH cohort was 54.8% male and 45.2% female. Racial distribution included 60.3% White, 11.1% African American, 7.9% Asian, and 7.9% Native Hawaiian/Pacific Islander; 11.1% identified as Hispanic/Latino ethnicity. Treatment patterns reflected the aggressive nature of CTCL complicated by HLH. Etoposide was administered to 61% of patients, followed by cyclophosphamide (51%), doxorubicin (41%), vincristine (37%), methotrexate (28%), romidepsin (18%), ifosfamide (14%), carboplatin (14%), and gemcitabine (13%). Vinblastine, crizotinib, belinostat, pembrolizumab, nivolumab, and duvelisib were each administered to fewer than 8% of patients.
Following 1:1 propensity score matching, CTCL patients who developed HLH experienced markedly inferior survival compared with matched CTCL patients without HLH. At 1 year, mortality risk was 49.18% in the HLH cohort compared with 5.82% in the non-HLH cohort (P < 0.0001). This survival disadvantage persisted over time. At the end of the 3-year follow-up period, mortality was 53.97% in the HLH cohort versus 10.28% in the non-HLH cohort, corresponding to survival probabilities of 37.83% and 86.94%, respectively (p<0.0001).
Conclusions:
HLH is an uncommon but devastating complication of CTCL, with the highest frequency observed in MF/SS and SPTCL and substantially lower rates in primary cutaneous CD30-positive T-cell proliferations. Patients who develop HLH are younger at presentation and experience dramatically worse long-term survival despite intensive cytotoxic therapy. The predominance of etoposide-based treatment suggests adherence to current HLH-directed management strategies; however, mortality remains unacceptably high. These findings represent one of the largest real-world analyses of CTCL-associated HLH and highlight the need for improved recognition, earlier diagnosis, and development of more effective therapeutic approaches in this high-risk population.
DISCLOSURES
Nikhila Sampath Kumar, MBBS: No relevant conflicts of interest to declare.